Cleerly

Executive Summary

Cleerly is a New York-based digital health company founded in 2017 that leverages artificial intelligence to perform non-invasive whole heart assessments for coronary artery disease. By analyzing cardiac CT scans, Cleerly's platform identifies, characterizes, and quantifies plaque buildup, enabling precise risk stratification for heart attacks. The company addresses a critical gap in cardiovascular care: traditional risk tools often miss early-stage or non-obstructive disease. Cleerly's AI-driven approach provides actionable insights for clinicians, potentially reducing unnecessary invasive procedures and improving patient outcomes through earlier intervention. The company operates at the intersection of AI, cardiovascular diagnostics, and digital health, positioning it for growth as value-based care and preventive medicine gain traction. Cleerly has raised significant private funding and is pursuing regulatory clearances and clinical validation to expand its commercial footprint. With a strong clinical evidence base and partnerships with leading health systems, the company is poised to become a standard in coronary artery disease assessment. However, it faces competition from established imaging firms and emerging AI diagnostics. Key near-term catalysts include expanded FDA clearances for plaque characterization, large-scale clinical outcome studies, and strategic collaborations that could accelerate adoption. Assuming continued execution, Cleerly has the potential to transform cardiac risk assessment and become a valuable asset in cardiovascular digital health.

Upcoming Catalysts (preview)

• Q2 2026FDA Clearance for Expanded Plaque Characterization Indication75% success
• Q3 2026Publication of Landmark Clinical Outcomes Study80% success
• Q4 2026Strategic Partnership with Major Health System or Payer65% success